Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to $125,000.

  • Journey Medical's Gains from Investment Securities rose 5.72% to $2.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.8 million, marking a year-over-year increase of 5.72%. This contributed to the annual value of $125,000 for FY2024, which is 30.94% down from last year.
  • According to the latest figures from FY2024, Journey Medical's Gains from Investment Securities is $125,000, which was down 30.94% from $181,000 recorded in FY2023.
  • In the past 5 years, Journey Medical's Gains from Investment Securities ranged from a high of $181,000 in FY2023 and a low of $110,000 during FY2020.
  • In the last 3 years, Journey Medical's Gains from Investment Securities had a median value of $168,000 in 2022 and averaged $158,000.
  • As far as peak fluctuations go, Journey Medical's Gains from Investment Securities soared by 43.64% in 2021, and later plummeted by 30.94% in 2024.
  • Over the past 5 years, Journey Medical's Gains from Investment Securities (Yearly) stood at $110,000 in 2020, then spiked by 43.64% to $158,000 in 2021, then increased by 6.33% to $168,000 in 2022, then climbed by 7.74% to $181,000 in 2023, then crashed by 30.94% to $125,000 in 2024.